Literature DB >> 15252303

An illustrated consensus on the classification of pancreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms.

Ralph H Hruban1, Kyoichi Takaori, David S Klimstra, N Volkan Adsay, Jorge Albores-Saavedra, Andrew V Biankin, Sandra A Biankin, Carolyn Compton, Noriyoshi Fukushima, Toru Furukawa, Michael Goggins, Yo Kato, Gunter Klöppel, Daniel S Longnecker, Jutta Lüttges, Anirban Maitra, G Johan A Offerhaus, Michio Shimizu, Suguru Yonezawa.   

Abstract

Invasive pancreatic ductal adenocarcinoma is an almost uniformly fatal disease. Several distinct noninvasive precursor lesions can give rise to invasive adenocarcinoma of the pancreas, and the prevention, detection, and treatment of these noninvasive lesions offers the potential to cure early pancreatic cancers. Noninvasive precursors of invasive ductal adenocarcinoma of the pancreas include pancreatic intraepithelial neoplasias (PanINs), intraductal papillary mucinous neoplasms (IPMNs), and mucinous cystic neoplasms. Diagnostic criteria, including a distinct ovarian-type stroma, and a consistent nomenclature are well established for mucinous cystic neoplasms. By contrast, consistent nomenclatures and diagnostic criteria have been more difficult to establish for PanINs and IPMNs. Because both PanINs and IPMNs consist of intraductal neoplastic proliferations of columnar, mucin-containing cells with a variable degree of papilla formation, the distinction between these two classes of precursor lesions remains problematic. Thus, considerable ambiguities still exist in the classification of noninvasive neoplasms in the pancreatic ducts. A meeting of international experts on precursor lesions of pancreatic cancer was held at The Johns Hopkins Hospital from August 18 to 19, 2003. The purpose of this meeting was to define an international acceptable set of diagnostic criteria for PanINs and IPMNs and to address a number of ambiguities that exist in the previously reported classification systems for these neoplasms. We present a consensus classification of the precursor lesions in the pancreatic ducts, PanINs and IPMNs.

Entities:  

Mesh:

Year:  2004        PMID: 15252303     DOI: 10.1097/01.pas.0000126675.59108.80

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  287 in total

1.  Comparison between MRI with MR cholangiopancreatography and endoscopic ultrasonography for differentiating malignant from benign mucinous neoplasms of the pancreas.

Authors:  Jiyoung Hwang; Young Kon Kim; Ji Hye Min; Woo Kyung Jeong; Seong Sook Hong; Hyun-Joo Kim
Journal:  Eur Radiol       Date:  2017-08-04       Impact factor: 5.315

2.  Pancreatic intraductal tubulopapillary neoplasm is genetically distinct from intraductal papillary mucinous neoplasm and ductal adenocarcinoma.

Authors:  Olca Basturk; Michael F Berger; Hiroshi Yamaguchi; Volkan Adsay; Gokce Askan; Umesh K Bhanot; Ahmet Zehir; Fatima Carneiro; Seung-Mo Hong; Giuseppe Zamboni; Esra Dikoglu; Vaidehi Jobanputra; Kazimierz O Wrzeszczynski; Serdar Balci; Peter Allen; Naoki Ikari; Shoko Takeuchi; Hiroyuki Akagawa; Atsushi Kanno; Tooru Shimosegawa; Takanori Morikawa; Fuyuhiko Motoi; Michiaki Unno; Ryota Higuchi; Masakazu Yamamoto; Kyoko Shimizu; Toru Furukawa; David S Klimstra
Journal:  Mod Pathol       Date:  2017-08-04       Impact factor: 7.842

Review 3.  Intraductal papillary mucinous neoplasia (IPMN) of the pancreas: its diagnosis, treatment, and prognosis.

Authors:  Robert Grützmann; Stefan Post; Hans Detlev Saeger; Marco Niedergethmann
Journal:  Dtsch Arztebl Int       Date:  2011-11-18       Impact factor: 5.594

4.  Clinicopathological characteristics and molecular analyses of multifocal intraductal papillary mucinous neoplasms of the pancreas.

Authors:  Hanno Matthaei; Alexis L Norris; Athanasios C Tsiatis; Kelly Olino; Seung-Mo Hong; Marco dal Molin; Michael G Goggins; Marcia Canto; Karen M Horton; Keith D Jackson; Paola Capelli; Giuseppe Zamboni; Laura Bortesi; Toru Furukawa; Shinichi Egawa; Masaharu Ishida; Shigeru Ottomo; Michiaki Unno; Fuyuhiko Motoi; Christopher L Wolfgang; Barish H Edil; John L Cameron; James R Eshleman; Richard D Schulick; Anirban Maitra; Ralph H Hruban
Journal:  Ann Surg       Date:  2012-02       Impact factor: 12.969

5.  Intraductal papillary mucinous neoplasm (IPMN) of the gastric-type with focal nodular growth of the arborizing papillae: a case of high-grade transformation of the gastric-type IPMN.

Authors:  Shinichi Ban; Yoshihisa Naitoh; Fumihiro Ogawa; Yoshihiko Shimizu; Michio Shimizu; Akihiro Yasumoto; Isamu Koyama
Journal:  Virchows Arch       Date:  2006-04-26       Impact factor: 4.064

6.  Glycosylation variants of mucins and CEACAMs as candidate biomarkers for the diagnosis of pancreatic cystic neoplasms.

Authors:  Brian B Haab; Andrew Porter; Tingting Yue; Lin Li; James Scheiman; Michelle A Anderson; Dawn Barnes; C Max Schmidt; Ziding Feng; Diane M Simeone
Journal:  Ann Surg       Date:  2010-05       Impact factor: 12.969

Review 7.  EGFR(S) inhibitors in the treatment of gastro-intestinal cancers: what's new?

Authors:  Shailender Singh Kanwar; Jyoti Nautiyal; Adhip P N Majumdar
Journal:  Curr Drug Targets       Date:  2010-06       Impact factor: 3.465

Review 8.  Precursors to pancreatic cancer.

Authors:  Ralph H Hruban; Anirban Maitra; Scott E Kern; Michael Goggins
Journal:  Gastroenterol Clin North Am       Date:  2007-12       Impact factor: 3.806

Review 9.  Intraductal papillary mucinous neoplasm originating from a jejunal heterotopic pancreas: report of a case.

Authors:  Hiroshi Okamoto; Fumiyoshi Fujishima; Kazuyuki Ishida; Ken Tsuchida; Takuya Shimizu; Hitoshi Goto; Akira Sato; Susumu Satomi; Hironobu Sasano
Journal:  Surg Today       Date:  2013-01-18       Impact factor: 2.549

10.  Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.

Authors:  Helen Court; Marc Amoyel; Michael Hackman; Kyoung Eun Lee; Ruliang Xu; George Miller; Dafna Bar-Sagi; Erika A Bach; Martin O Bergö; Mark R Philips
Journal:  J Clin Invest       Date:  2013-11       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.